SCHEMBL334273

SCHEMBL334273

O=C(CCC[C@@H]1CO1)Nc1cccc(Br)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.54
GAA P10253 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HTT P42858 1/20 0.50
ATM Q13315 1/20 0.50
MAPT P10636 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
PRMT5 O14744 1/20 0.47
WDR77 Q9BQA1 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335818 0.82 MAPT (0.50) SMN1; SMN2GAAALDH1A1MEN1KMT2A
SCHEMBL22743048 0.79 L3MBTL1 (0.64) SMN1; SMN2GAAL3MBTL1ALDH1A1MEN1
SCHEMBL30087930 0.77 GAA (0.62) SMN1; SMN2GAAL3MBTL1ALDH1A1MEN1
SCHEMBL22743026 0.77 L3MBTL1 (0.63) SMN1; SMN2GAAL3MBTL1ALDH1A1MEN1
SCHEMBL22743039 0.77 GAA (0.62) SMN1; SMN2GAAL3MBTL1ALDH1A1MEN1
SCHEMBL7827916 0.77 MEN1 (0.68) SMN1; SMN2GAAL3MBTL1ALDH1A1MEN1
SCHEMBL21805191 0.77 GAA (0.62) SMN1; SMN2GAAL3MBTL1ALDH1A1MEN1
SCHEMBL27710689 0.77 GAA (0.71) SMN1; SMN2GAAL3MBTL1ALDH1A1MEN1
SCHEMBL16010975 0.76 EGFR (0.63) SMN1; SMN2GAAL3MBTL1MEN1KMT2A
SCHEMBL22743462 0.76 GAA (0.60) SMN1; SMN2GAAL3MBTL1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 SMN1; SMN2 3120/4885GAA 551/4885L3MBTL1 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.